A Direct, Efficient Method for the Preparation of siRNAs Containing Ribo-like North Bicyclo[3.1.0]hexane Pseudosugars by Terrazas, Montserrat et al.
“A direct, efficient method for the preparation of siRNAs containing ribo-like North 
bicyclo[3.1.0]hexane pseudosugars” Terrazas, M., Aviñó, A., Siddiqui, M., Marquez, 
V., Eritja, R. Org. Lett., 13(11), 2888-2891 (2011). 
PMID: 21553811, doi: 10.1021/ol200909j 
 
A direct, efficient method for the preparation of siRNAs 
containing ribo-like North bicyclo[3.1.0]hexane pseudosugars 
 
Montserrat Terrazas,† Anna Aviñó,† Maqbool A. Siddiqui,‡ 
Victor E. Marquez,*,‡ and Ramon Eritja*,† 
 
Institute for Research in Biomedicine (IRB Barcelona), Networking Center on 
Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), and Institute for 
Advanced Chemistry of Catalonia (IQAC), Spanish Research Council (CSIC), Cluster 
Building, Baldiri i Reixac 10, E-08028 Barcelona, Spain, and Laboratory of Chemical 
Biology, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, 
MD  21702 USA. 
Email Address: recgma@cid.csic.es 
 
Abstract: 
 
 
 
 
 
 
 
 
 
 
An efficient method for the preparation of siRNAs modified with ribo-like North 
bicyclo[3.1.0]hexane pseudosugars is described. The combined use of 2'-O-(2-
cyanoethoxymethyl) (CEM) and 2'-O-TBDMS protection was successfully employed 
for RNA synthesis with the added advantage that both groups were efficiently removed 
in a single step. The resulting North ribo-methanocarba-modified siRNAs are 
compatible with the intracellular RNAi machinery and can mediate specific degradation 
of target mRNA. 
 
Nucleotide analogues that exhibit the North-type sugar puckering1 and possess the 
overall A-RNA-type conformation have attracted much interest in the field of RNA 
interference (RNAi) therapy.2 RNAi is a sequence-specific RNA silencing mechanism3 
triggered by double-stranded RNA or short interfering RNA molecules (siRNA), which 
are formed by a sense and a guide strand.4 Within the cells, an RNA-induced silencing 
complex (RISC)5 unwinds the siRNA duplex and uses the guide strand as a template to 
find the complementary target mRNA,6 an event that induces the endonucleolytic 
cleavage of the mRNA7 and prevents its translation into protein. For efficient gene 
silencing to take place, the guide siRNA:mRNA duplex must adopt an A-type helical 
structure.8 In order to fulfill these requirements and to improve target-binding affinity, 
several North-locked nucleotide building blocks have been designed, synthesized, and 
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incorporated into siRNAs.9 Examples are 2'-O-alkylated RNAs,8b,10 2'-fluoro-
RNAs,8b,10a,11 and Locked Nucleic Acids (LNA); the latter containing a methylene 
bridge between the 2' oxygen and the 4' carbon.12 In particular, LNAs have been widely 
explored and it is well known that LNA-modified siRNAs efficiently induce the RNAi 
process and increase the thermodynamic and serum stability of RNA duplexes to a great 
extent.13 
Another candidate for introducing new features into siRNAs without perturbing the A-
type helical structure they require for activity is the North-locked form of nucleotide 
analogues based on a carbocyclic bicyclo[3.1.0]hexane system [methanocarba (MC) 
nucleosides]. Preliminary studies on the effect of North 2’-deoxy-MC nucleosides on 
the RNAi process have shown that these pseudonucleosides are accepted by the RNAi 
machinery.14 However, the effect of a hydroxyl group at the 2’ position of any of the 
modified sugars, or the carbocyclic pseudosugar, on the RNAi process has never been 
investigated. The design and synthesis of North ribo-MC nucleosides (Figure 1) has 
been reported.15 Nevertheless, these derivatives have never been incorporated into 
RNA strands.  
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Figure 1. North ribo-methanocarba cytidine monomer (CN) 
 
Herein we describe a synthetic strategy for the preparation of conveniently 2'-O-
protected phosphoramidite of North ribo-MC cytidine (CN) (Figure 1). We also 
describe its incorporation into mixed 2'-O-protected RNA strands and the removal of 
the 2'-O-protecting groups of the RNAs in a single step. This approach permits an easy 
access to the preparation of North ribo-MC cytidine-modified siRNAs with potential 
therapeutic applications. 
An important challenge in the preparation of RNA strands modified with North ribo-
MC is the protection of the 2'-OH group of the pseudoribose. Preliminary studies on the 
reactivity of the 2'-OH group of North ribo-MC cytidine carried out in our group have 
shown that the 3'-OH is much more reactive than the 2'-OH group (data not shown). 
Thus, in contrast to what has been reported for a great number of nucleoside 
derivatives,16 the direct protection of the 2'-OH group of 5'-O-protected ribo-MC 
cytidine derivatives with a free 3'-hydroxyl group becomes a serious problem.  The 
attempted strategy was to employ a 3',5'-O-disiloxan diprotected intermediate with a 
free 2'-OH group (1, Scheme 1). Our first try involved the protection of the free 2'-OH 
in 1 with a benzoyl group. However, this route was abandoned due to the rapid 
migration of the 2'-O-benzoyl from the 2'-OH to the 3'-OH after deprotection.  
A wide variety of 2'-O-protecting groups have been developed for RNA synthesis.16,17 
For example, fluoride-labile protecting groups such as tert-butyldimethylsilyl 
(TBDMS),17a [(triisopropylsilyl)oxy]methyl (TOM)17b and 2-cyanoethoxymethyl 
(CEM)17c groups, or the photo-labile [(2-nitrobenzyl)oxy]methyl group17d among 
others.16 TBDMS and TOM are popular 2'-OH protecting groups whose 
phosphoramidites are commercially available. We decided to use the cheaper 2'-O-
TBDMS-protected phosphoramidites of natural ribonucleosides for RNA synthesis. 
However, for the protection of the 2'-OH group of the 3',5'-O-disiloxan protected MC 
nucleoside 1, the fluoride-labile TBDMS and TOM groups had to be avoided since the 
disiloxane protecting group is also removed by a fluoride reagent like TBAF. To 
overcome these problems, the group of Wada et al. have found a way to prevent the 
removal of the CEM group during the removal of the disiloxan group of 3',5'-O-
disiloxan-2'-O-CEM-protected nucleosides, by treatment with TBAF in the presence of 
AcOH.18 
As for RNA synthesis, removal of the CEM group from fully 2'-O-CEM-protected RNA 
strands has been successfully achieved under aprotic conditions.19 In our search for a 
synthetic method that would allow ready cleavage of the 2'-O-protecting group of the 
MC nucleoside and the 2'-O-TBDMS protecting group of natural nucleosides from the 
final RNA product in only one step, we decided to focus on the CEM group.  
 
Scheme 1. Preparation of 2'-O-CEM-protected ribo-MC cytidine building block 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The synthesis of compound 1 is relatively straightforward and it is described in the 
supplementary section. As described in Scheme 1, compound 1 was treated with 2-
cyanoethyl methylthiomethyl ether to give the desired 2'-O-CEM-3',5'-O-disiloxan-
protected derivative 2 in 73% yield. Following the fluoride-catalyzed removal of the 
disiloxan protecting group the desired 2'-O-CEM protected diol 3 was obtained in 90% 
yield. The 5' hydroxyl group was then protected by a 4,4'-dimethoxytrityl group (DMT) 
and the resulting 5'-O-DMT-2'-O-CEM-protected nucleoside 4 was converted into the 
desired phosphoramidite (5). 
With compound 5 at hand we proceeded to incorporate this nucleotide building block 
(CN) into different positions in place of the natural ribocytidine along a 21-mer RNA 
guide strand that targets the Renilla luciferase mRNA by using a DNA/RNA 
synthesizer. The solid-phase synthesis was carried out on a 0.2 mol scale with a 
coupling time of 10 min. For CN-modified RNAs, P(III) to P(V) oxidation was 
performed with a solution of 10% tert-butyl hydroperoxide in acetonitrile/water (96:4). 
Commercially available succinyl polystyrene functionalized with 5'-O-DMT-2'-
deoxythymidine was used as the solid support and tetrazole as the activator. 
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Phosphoramidites of 2'-O-TBDMS protected natural ribonucleosides (A, U, G and C) 
were obtained from commercial sources. We prepared RNA guide strands containing no 
substitutions (6, wt), one CN substitution at position 8 (7) and two CN substitutions 
spaced-out along the guide strand at positions 8 and 15 (8). We also prepared the 
corresponding unmodified sense strand (Table 1). 
After RNA synthesis, the DMT-on polystyrene solid support was treated with a mixture 
of 33% ammonia solution and ethanol [3:1 (v/v)] for 24 h at 35 ºC16c for the cleavage 
from the polystyrene solid support and the removal of the phosphate-protecting and 
base-protecting groups. In the next step, the 2’-O-TBDMS protecting group of 
unmodified guide (6) and sense strands was completely removed by treatment with 1 M 
TBAF/THF for 12 h. 
 
Table 1. Sequences of RNAs and Tm data 
 
1 3'-TTAAAAAGAGGAAGAAGUCUA (sense)  
2 5'-UUUUUCUCCUUCUUCAGAUTT (guide, 6, wt) 67.6 
3 5'-UUUUUCUCNCUUCUUCAGAUTT (guide, 7)   65.9 
4 5'-UUUUUCUCNCUUCUUCNAGAUTT (guide, 8) 64.5 
Tms were measured in 15 mM HEPES-KOH (pH 7.4), 1 mM MgCl2 and 50 mM KOAc. 
 
For the removal of 2’-O-TBDMS and 2’-O-CEM protecting groups of RNAs 7 and 8, 
10% n-propylamine and 1% of bis(2-mercaptoethyl) ether in 1M TBAF/THF was used 
instead of 1 M TBAF/THF to prevent formation of CEM adducts, a side reaction 
reported by Ohgi et al.14 These authors report complete removal of 2’-O-CEM 
protecting groups of fully 2’-O-CEM protected RNA strands after 6 h at r.t. Under these 
conditions, we obtained mixtures of 2'-O-protected and 2'-O-deprotected RNAs (as 
evaluated by HPLC). We increased the reaction time (to 12, 15 and 24 h) and after 
shaking at room temperature for 24 h, HPLC analysis of the crude oligo showed a single 
main peak corresponding to the fully deprotected product and only small amounts of 
shorter products (Figure 2A). Fully 2’-O-deprotected RNAs (6, 7, 8 and sense) were 
purified by reverse phase semi-preparative HPLC in the DMT-on mode. Finally, the 
DMT-on products were treated with 80% AcOH solution to remove the DMT group and 
the de-protected products were desalted on NAP columns. The desired products were 
obtained in good overall yields (7, 58%; 22 OD; 8, 35%, 13 OD).  
 
 
 
Figure 2. HPLC analysis of RNA 7. (A) Unpurified fully deprotected RNA 7. (B) 
Purified fully deprotected RNA 7. 
 
RNA strands 7 and 8 were treated with nuclease P1 and then alkaline phosphatase, and 
the digestion products were analyzed by HPLC. No modified ribonucleosides (2’-O-
CEM protected ribo-MC cytidine or 2’-O-TBDMS protected U, A, C and G) were 
observed; showing that complete removal of the CEM and TBDMS protecting groups 
and base-protecting groups was achieved.  
Finally, in order to study the effect of the ribo North MC cytidine substitution on the 
RNA interference process, we carried out separate RNAi studies in SH-SY5Y cells with 
siRNA duplexes containing each of the modified guide strands (7 and 8), as well as with 
the unmodified (wt) guide RNA (6). Experiments were carried out in triplicate. The 
cells were first transfected with dual reporter plasmids that express Renilla luciferase 
(the target) and non-targeted firefly as an internal control. The effects of the different 
siRNAs on luciferase expression were evaluated using 26-0.03 nM siRNA 
concentrations in the cell media and measuring luciferase responses after 22 h. The 
results show that the RNAi machinery is not impaired by the North MC riboC 
modification (Figure S27). The best results were obtained for siRNA containing one 
substitution in the guide strand (7), which showed activity comparable to that of wt 
siRNA (6). To confirm the specificity of the observed effects, sequence-scrambled 
siRNAs were used (Table S1). As expected, scrambled sequences gave no Renilla 
inhibition (Figure S27). Thermal denaturation studies suggested that the CN 
modification caused a slight destabilization of the siRNA duplex (T = –1.6 ºC per 
substitution; Table 1). However, such small destabilization did not significantly affect 
RNAi activity. 
In conclusion, in this work we have reported an strategy for (i) the preparation of North 
ribo-MC nucleosides conveniently protected at the 2’-OH position, (ii) their 
incorporation into mixed 2'-O-protected RNA strands and (iii) the removal of the 2'-O-
protecting groups of the RNA in only one step. To the best of our knowledge, this is the 
first time that the synthesis and one-step de-protection of a 2'-O-TBDMS/2'-O-CEM 
oligoribonucleotides has been described.  
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Materials and Methods 
 
Common chemicals and solvents in addition to 2-cyanoethyl 
diisopropylphosphoramidochloridite were purchased from commercial sources and used 
without further purification. Anhydrous solvents and deuterated solvents (CDCl3, 
CD3OD and DMSO-d6) were obtained from reputable sources and used as received. 
Reagents for oligonucleotide synthesis including 2’-O-TBDMS-protected 
phosphoramidite monomers of ABz, CAc, Gdmf and U, the 5’-deblocking solution (3% 
TCA in CH2Cl2), activator solution (0.4M 1H-tetrazole in MeCN), Cap A solution 
(acetic anhydride/pyridine/tetrahydrofuran (1:1:8), Cap B solution [10% N-
methylimidazole in tetrahydrofuran), oxidizing solution (0.01M iodine in 
tetrahydrofuran/pyridine/water (7:2:1) or 70% tert-butyl hydroperoxide in water, which 
was diluted to 10% with acetonitrile (synthesis grade) prior to use] and succinyl 
polystyrene  functionalized with 5’-O-DMT-2’-deoxythymidine were purchased from 
commercial sources and used as received. 
Nuclease P1 and bacterial alkaline phosphatase were commercially available and used 
without further purification. 
All reactions were carried out under argon atmosphere in oven-dried glassware. Thin-
layer chromatography was carried out on aluminium-backed Silica-Gel 60 F254 plates. 
Column chromatography was performed using Silica Gel (60 Å, 230 x 400 mesh). NMR 
spectra were measured on Varian Mercury-400 or Varian-300 instruments. Chemical 
shifts are given in parts per million (ppm); J values are given in hertz (Hz). All spectra 
were internally referenced to the appropriate residual undeuterated solvent. 
 
RP-HPLC purifications were performed using a Nucleosil 120-10 C18 column (250x4 
mm).  
 
HRMS of compound 5 was performed  on a LC/MSD-TOF (Agilent technologies) high 
resolution mass spectometer by Servei d’Espectrometria de Masses (Universitat de 
Barcelona).  HRMS of compounds 3 and 4 was performed by (MALDI, positive ion) on 
a Shimadzu Axima-CFR curved field reflection TOF mass spectrometer using CHCA as 
the MALDI matrix.APCI MS analyses were conducted on an Agilent LC-MS using 
flow-injection analysis.  Low resolution MS (FAB) for compounds 2s – 8s and 1 and 2 
was performed on a VG 7070E mas spectrometer and at an  accelerating voltage of +8 
kV and ionization was effected by a beam of xenon atoms. 
 
MALDI-TOF spectra were performed using a Perseptive Voyager DETMRP mass 
spectrometer, equipped with nitrogen laser at 337 nm using a 3ns pulse. The matrix 
used contained 2,4,6-trihydroxyacetophenone (THAP, 10 mg/mL in ACN/ water 1:1) 
and ammonium citrate (50 mg/mL in water). 
 
 
 
 
 
 
 
 
 
 
Synthetic scheme 
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Preparation of  2s 
A solution of cyclopentenone 1s (3.92 g, 9.27mmol) in anhydrous methanol (70 mL) 
was treated with Cerium(III) chloride heptahydrate (3.20 g, 8.58 mmol ). The flask was 
cooled over ice and treated with portions of sodium borohydride (0.390 g, 10.30 mmol). 
After 15 minutes, the pH was brought to 4 with acetic acid. Immediately after, water (40 
mL) was added and the mixture was extracted with ether (2 ? 100 mL). The combined 
ether extract was washed with brine (2 ? 60 mL), dried (MgSO4) and concentrated in 
vacuo. The crude product was purified by flash chromatography over silica gel using 10 
? 20% EtOAc in hexanes to give 3.38 g (86.0%) of 2s as an oil: 1H-NMR (400 MHz, 
CDCl3) δ 7.51-7.61 (m, 4 H), 7.27-7.35 (m, 6 H), 5.76 (m, 1 H), 4.79 (d, J = 5.5 Hz, 1 
H), 4.67 (td,  J = 6.3, 0.8 Hz, 1 H), 4.48 (br s, 1 H), 4.31 (dm, J = 15.2 Hz, 1 H), 4.21 
(dm, J = 15.2 H, 1 H), 2.60 (br s, 1 H), 1.28 (s, 3 H), 1.26 (s, 3 H), 1.00 (s, 9 H); 13C 
NMR (100 MHz, CDCl3) δ 145.2, 135.5, 133.28, 129.7, 129.6, 129.29, 127.7, 112.4, 
82.8, 77.9, 73.3, 60.8, 27.6, 26.7, 19.2; FABMS m/z (relative intensity) 425.2 (MH+, 
17), 463.2 (MK+, 100). Anal. Calcd. for C25H32O4Si: C, 70.72; H, 7.60. Found: C, 
70.82; H, 7.60. 
 
 
Preparation of 3s 
An ice-cold solution of 2s (10.89 g, 25.89 mmol) in anhydrous CH2Cl2 (150mL) was 
stirred and treated with a solution of Et2Zn in hexane (1M , 70mL, 70 mmol) and CH2I2 
(6 mL, 74.3 mmol). After 15 min, the ice bath was removed while stirring continued for 
1.5 h.  The reaction mixture was quenched with a saturated aqueous solution of NH4Cl 
(100 mL) and extracted with CH2Cl2 (2 ? 100 mL). The combined organic layer was 
washed with saturated aqueous NaHCO3 (2 ? 100mL), water (2 ? 100 mL), dried 
(MgSO4) and concentrated in vacuo. The crude product was purified by flash 
chromatography over silica gel using 10 ? 25% EtOAc in hexanes to give 8.42 g 
(74.8%) of 3s as a thick oil: 1H-NMR (400 MHz, CDCl3) δ 7.60-7.65 (m, 4 H), 7.34-
7.42 (m, 6 H), 5.00 (dd, J = 7.0, 1.2 Hz, 1 H), 4.54 (dt, J = 7.4, 0.8 Hz, 1 H), 4.45 (br t,  
J ≈ 6 Hz, 1 H), 4.06 (d, J = 11.3 Hz, 1 H), 3.28 (d, J = 11.3 Hz, 1 H), 2.30 (br s, 1 H), 
1.60 (m, 1 H), 1.53 (s, 3 H), 1.31 (s, 3 H), 1.08 (irregular t, J ≈ 5 Hz, 1 H), 1.00 (s, 9 H), 
0.53 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 135.5, 133.6, 129.7, 127.7, 112.7, 81.1, 
79.7, 71.0, 65.3, 35.5, 32.8, 26.9, 26.1, 24.6, 19.2, 10.3 FABMS m/z (relative intensity) 
477.2 (MK+, 100). Anal. Calcd. for C26H34O4Si: C, 71.19%; H, 7.81. Found: C, 71.03; 
H, 8.00. 
 
 
Preparation of 4s 
An ice-cold solution of 3s (8.33g, 18.99 mmol) in dry pyridine (100 mL) was treated 
with CH3SO2Cl (3.6 mL, 46.5 mmol). After 10 min, the reaction mixture was warmed 
to ambient temperature and stirred for 1.5 h. The solvent was removed in vacuo and the 
crude product was purified by flash chromatography using 20 ? 33 % EtOAc in 
hexanes to give 9.80 g (99.8%) of the intermediate mesylate. This intermediate (9.80 g, 
19.1 mmol) was immediately dissolved in anhydrous DMF (80 mL) and treated with 
NaN3 (12.5 g, 192.2 mmol). The reaction mixture was heated to 100 °C for 2 h, cooled 
to ambient temperature, quenched with water (100 mL) and extracted with Et2O (2 ? 
150 mL). The combined ether layer was dried (MgSO4), concentrated in vacuo and 
purified by flash chromatography over silica gel using 0 ? 5% EtOAc in hexanes to 
give 7.57 g (86.1%) of 4s as a thick oil: 1H-NMR (400 MHz, CDCl3) δ 7.64-7.68 (m, 4 
H), 7.35-7.45 (m, 6 H), 5.03 (dd, J = 7.0, 1.4 Hz, 1 H), 4.50 (dd, J = 7.0, 1.4 Hz, 1 H), 
4.03 (d, J = 10.9 Hz, 1 H), 3.87 (s, 1 H), 3.42 (d, J = 10.9 Hz, 1 H), 1.57 (ddd, J = 9.3, 
4.7, 1.6 Hz, 1 H), 1.44 (s, 3 H), 1.26 (s, 3 H), 1.06 (s, 9 H), 0.92 (dd, J = 5.4, 4.3 Hz, 1 
H), 0.75 (ddd, J = 7.0, 5.4, 1.6 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 135.6, 133.5, 
133.4, 129.7, 127.7, 111.7, 87.6, 80.9, 65.5, 64.6, 37.9, 29.2, 26.8, 25.9, 24.3, 19.3, 
11.9; FABMS m/z (relative intensity) 502.2 (MK+, 35), 464.2 (MH+, 5), 406.2 (MH+ – 
(CH3)2CO). Anal. Cacld. for C26H33N3O3Si: C, 67.35; H, 7.17; N, 9.06. Found: C, 
67.21; H, 7.15; N, 9.04. 
 
 
 
Preparation of 5s 
A stirred, argon-flushed solution of 4s (2.13 g, 4.59 mmol) in CH3OH:CH2Cl2 (1:1, 40 
mL) was treated with 0.2 g of Lindlar’s catalyst. The inert gas was evacuated and 
replaced with a hydrogen-filled balloon. After 18 h, the reaction was filtered over short 
pad of celite and the solvent was evaporated to dryness.  The crude product was purified 
by flash chromatography over silica gel using 5% EtOAc in hexanes ? 100% EtOAc to 
give 1.76 g (88.0%) of 5s as a thick oil: 1H-NMR (400 MHz, CDCl3) δ 7.65-7.70 (m, 4 
H), 7.35-7.45 (m, 6 H), 5.10 (dd, J = 7.0, 1.2 Hz, 1 H), 4.35 (dd, J = 7.0, 1.5 Hz, 1 H), 
4.14 (d, J = 10.9 Hz, 1 H), 3.34 (s, 1 H), 3.30 (d, J = 10.9 Hz, 1 H), 1.47 (s, 3 H), 1.42 
(br s, 2 H), 1.26 (m, 4 H), 1.06 (s, 9 H), 0.91(irregular t, J ≈ 5 Hz, 1 H), 0.60 (ddd, J = 
8.9, 5.4, 1.6 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 135.6, 133.6, 129.7, 127.7, 111.0, 
91.2, 80.8, 65.5, 56.7, 37.3 33.4, 26.9, 26.0, 24.3, 19.3, 12.6; FABMS m/z (relative 
intensity) 467.72 (MK+, 10), 438.3 (MH+, 20). Anal. Calcd. for C26H35NO3Si: C, 71.35; 
H, 8.06; N, 3.20. Found: C, 71.15; H, 8.10; N, 3.17. 
 
 
Preparation of 6s 
A solution of dried AgNCO (4.3 g, 28.6mmol) in anhydrous benzene (60 mL) was 
maintained under argon and treated with freshly prepared 3-methoxyacryloyl chloride 
(1.80 g, 14.93 mmol), which was added drop-wise at ambient temperature. The mixture 
was then heated to reflux for 1 h and again allowed to reach ambient temperature.  After 
the mixture settled, the supernatant was added via syringe to a stirred, ice-cold solution 
of 5s  (3.0 g, 6.85 mmol) in anhydrous CH2Cl2 (50 mL) that was maintained under an 
argon atmosphere. The solution was allowed to warm up to ambient temperature and 
was stirred for 1.5 h. The solvent was then evaporated and the residue was purified by 
flash chromatography over silica gel using 20% ? 50% EtOAc in hexanes to give 3.70 
g (95.6%) of the 3-methoxyacryloyl ureido intermediate. This intermediate was 
dissolved in ethanol (100 mL) and treated with 2N aqueous HCl (10 mL). The solution 
was then heated to reflux overnight and after cooling to ambient temperature the solvent 
was removed in vacuo. The residue was triturated with EtOAc (10 mL) and the solid 
obtained was filtered and washed with hexanes (5 mL).  After drying under vacuum, 
1.60 g (96.4%) of the free, unprotected uracil nucleoside was obtained: 1H-NMR (400 
MHz, DMSO-d6) δ 7.86 (d, J = 8.0 Hz, 1 H), 5.50 (d, J = 8.0 Hz, 1 H), 4.98 (d, J = 4.3 
Hz, 1 H, D2O exchanged), 4.90 (t, J = 5.0 Hz, 1 H, D2O exchanged), 4.54 (s, 1 H), 4.29-
4.38 (m, 2 H; d at 4.30, J = 6.6, 1.6 Hz after D2O), 3.95 (dd, J = 11.3, 5.0 Hz, 1 H; d at 
3.92, d after D2O), 3.56 (br t, 1 H), 3.02 (dd, J = 11.3, 4.8 Hz, 1 H; d 3.00 after D2O), 
1.09-1.15 (m, 2 H; irregular dd at 1.14 and irregular t at 1.10 after D2O), 0.49 (m, 1 H; 
ddd, J = 8.5, 4.3, 1.6 Hz after D2O); FABMS m/z (relative intensity) 255.1 (MH+, 100), 
113 (bH2+, 35).  Because this material had a trace impurity, the combined total from this 
reaction and that of a second reaction (2.43 g, 9.55 mmol) was suspended in anhydrous 
pyridine (60mL) and treated with Ac2O (6.0 mL, 63.5 mmol). After stirring for 1.5 h, 
the solvent was removed in vacuo, co-evaporated thrice with toluene (3 ?10mL) and 
the crude residue was purified by flash chromatography over silica gel using 50% 
EtOAc in hexanes ? 100% EtOAc to give 3.18 g (88.9%) of 6s as a pure oil: 1H-NMR 
(400 MHz, CDCl3) δ 8.98 (br s, 1 H), 7.35 (d, J = 8.2 Hz, 1 H), 5.70 (dd, J = 8.2, 2.3 
Hz, 1 H), 5.66 (dd, J = 7.4, 1.6 Hz, 1 H), 5.16 (dt, J = 7.4, 1.6 Hz, 1 H), 4.60 (s, 1 H), 
4.40 (d, J = 12.1 Hz, 1 H), 3.94 (d, J = 12.1 Hz, 1 H), 2.07 (s, 3 H), 2.02 (s, 6 H), 1.46 
(dd, J = 8.6, 4.3 Hz, 1 H),  1.23 (dd, J = 6.2, 4.3 Hz, 1 H), 0.97 (ddd, J = 8.6, 6.2, 1.6 
Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 170.6, 170.0, 169.0, 162.8, 150.2, 141.6, 
102.8, 76.1, 72.8, 65.2, 64.5, 33.2, 23.8, 20.7, 20.5, 20.4, 12.6; FABMS m/z (relative 
intensity) 381.1 (MH+, 100), 113 (bH2+, 10). Anal. Calcd. for C17H20N2O8: C, 53.68; H, 
5.30; N, 7.37. Found: C, 53.56; H, 5.25; N, 7.29. 
 
 
Preparation of 7s 
A stirred solution of 6s (3.17 g, 8.33 mmol), Et3N (12.10 mL, 86.80 mmol) and triazole 
(5.90 g, 85.40 mmol) in acetonitrile (150 mL) was cooled over an ice bath.  POCl3 (1.60 
mL, 17.40 mmol) was added dropwise and after 15 min the ice bath was removed while 
stirring continued overnight. The solvent was evaporated and the residue was dissolved 
in EtOAc (300 mL), washed with water (2 ?100 mL) and dried (MgSO4).  After 
removing the solvent in vacuo, the crude residue was purified by flash chromatography 
over silica gel using 50% EtOAc in hexanes ? 100% EtOAc to give 2.94 g (81.8%) of 
the triazole intermediate as a foam. This material was dissolved in 1,4-dioxane (60 mL) 
and treated with concentrated NH4OH (15 mL). After stirring at ambient temperature 
overnight, the solvent was removed in vacuo and the residue was co-evaporated with 
ethanol (2 ?10 mL) and toluene (2 ? 25 mL). The residual material was dissolved in a 
small amount of methanol and treated in a sealed flask with saturated methanolic 
ammonia. The mixture was stirred at ambient temperature overnight and after all 
volatiles were removed the solid obtained was purified by flash chromatography over 
silica gel using 25% ? 50% MeOH in CH2Cl2 to give 1.23 g (71.5%) of 7s as a solid, 
mp 242-243 ºC; [α]20D = +13.1 (c 0.50 DMF). The 1H-NMR spectrum in Figure S11 is 
in DMSO-d6; a better resolution was obtained after D2O exchange: 1H-NMR (400 MHz, 
DMSO-d6 + D2O) δ 7.80 (d, J = 7.4 Hz, 1 H), 5.67 (d, J = 7.4 Hz, 1 H), 4.57 (s, 1 H), 
4.28 (d, J = 5.8 Hz, 1 H), 3.93 (d, J = 11.3 Hz, 1 H), 3.46 (d, J = 6.6 Hz, 1 H), 3.02 (d, J 
= 11.3 Hz, 1 H), 1.08 – 1.11 (m, 2 H), 0.48 (br  dd, J = 10.1, 6.2 Hz, 1 H); 13C NMR 
(100 MHz, DMSO-d6 + D2O) δ 165.7, 155.9, 142.8, 93.8, 76.6, 70.6, 63.3, 62.5, 37.2, 
22.8, 11.1; FABMS m/z (relative intensity) 254.1 (MH+, 100), 112.1 (bH2+, 40).  Anal. 
Calcd. for C11H15N3O4•0.25H2O: C, 51.26; H, 6.06; N, 16.30. Found: C, 51.50; H, 6.10; 
N, 16.20. 
 
 
Preparation of 8s 
A stirred suspension of nucleoside 7s (0.96 g, 3.79 mmol) in anhydrous pyridine (60 
mL) was treated with Me3SiCl (4.80 mL, 37.86 mmol). After 15 min, benzoyl chloride 
(2.40 mL, 20.65 mmol) was added and kept at ambient temperature for 20 h.  After 
cooling over an ice-bath, the reaction was quenched with water (4 mL) and concentrated 
NH4OH (10 mL).  After 20 min, the ice bath was removed and stirring continued for 20 
min.  After removing all volatiles in vacuo the residue was dissolved in water (150 mL) 
and washed with Et2O (2 ? 75mL).  The aqueous layer was concentrated and 
lyophilized and then purified twice by flash chromatography over silica gel using 2 
?10% MeOH in CH2Cl2 to give 0.686 g (50.8%) of 8s as a foam. The 1H-NMR 
spectrum in Figure S12 is in DMSO-d6; a better resolution was obtained after D2O 
exchange: 1H-NMR (400 MHz, DMSO-d6 + D2O) δ 8.37 (d, J = 7.0 Hz, 1 H), 7.92 (d, J 
= 7.8 Hz, 2 H), 7.44-7.59 (m, 3 H), 7.26 (d, J =  7.4 Hz, 1 H),  4.69 (s, 1 H), 4.35 (dd, J 
= 6.6, 1.2 Hz, 1 H),  3.97 (d, J = 11.3 Hz, 1 H), 3.60 (m, 1 H), 3.05 (d, J = 11.3 Hz, 1 
H), 1.23 – 1.26 (irregular dd, 1 H),  1.20 (irregular t, 1 H), 0.55 (ddd, J = 8.1, 4.7, 1.6 
Hz, 1 H); 13C NMR (100 MHz, DMSO-d6 + D2O) δ 167.7, 162.8, 155.4, 147.0, 133.6, 
133.1, 128.8, 96.3, 76.1, 70.4, 64.3, 62.4, 55.3, 37.3, 22.7, 11.3; FABMS m/z (relative 
intensity) 358.1 (MH+, 100), 216.1 (bH2+, 65). Anal. Calcd for C18H19N3O5•0.40CH2Cl2: 
C, 56.47; H, 5.09; N, 10.73. Found: C, 56.35; H, 5.24; N, 10.95. 
Preparation of 1 
A suspension of nucleoside 8s (0.55g, 1.53 mmol) in anhydrous pyridine (20 mL) 
containing imidazole (0.14 g, 2.05 mmol) was treated with 1,3-dichlorotetraisopropyl 
disiloxane (TIPS-Cl , 0.90mL, 2.85 mmol). The mixture was stirred at ambient 
temperature for 1.5 h and then quenched with water (50 mL). Following the extraction 
with EtOAc (2 ? 75 mL), the combined organic layer was dried (MgSO4), concentrated 
in vacuo and purified by flash chromatography over silica gel using 50 ? 80% EtOAc 
in hexanes to give 0.765 g (82.80%) of 1 as foam: 1H-NMR (400 MHz, CDCl3) δ 8.80 
(br s, 1 H), 7.96 (d, J = 7.4 Hz, 1 H), 7.85 (v br d, J = 5.0 Hz, 2 H), 7.43-7.57 (m, 3 H), 
4.85 (s, 1 H), 4.83 (dd, J = 6.6, 1.2 Hz, 1 H),  4.05 (d, J = 12.5 Hz, 1 H), 3.88 (d, J = 6.6 
Hz, 1 H), 3.59 (d, J = 12.5 Hz, 1 H),  2.78 (s, 1 H), 1.50 (dd, J = 3.8, 5.6 Hz, 1 H), 1.30 
(ddd, J = 1.2, 3.6, 8.9 Hz, 1 H), 0.90- 1.08 (m, 28 H), 0.55 (ddd, J = 1.6, 5.6, 8.7Hz, 1 
H); 13C NMR (100 MHz, CDCl3) δ 160.8, 145.1, 132.1, 128.0, 126.6, 95.7, 70.6, 63.5, 
62.9, 35.2, 24.3, 24.1, 16.4, 16.3, 16.1, 16.0, 12.4, 12.0, 12.1, 11.8, 8.9; FABMS m/z 
(relative intensity) 600.3 (MH+, 100), 216.1 (bH2+, 68).  Anal. Calcd. for 
C30H45N3O6Si2: C, 60.07; H, 5.56; N, 7.00. Found: C, 60.01; H, 5.69; N, 6.76. 
 
Preparation of 2 
A stirred solution of 1 (0.360 g, 0.60 mmol) in anhydrous THF (25 mL) over molecular 
sieves (4A, 0.60 g) was treated with a freshly prepared solution of 2-cyanoethyl 
methylthiomethyl ether (0.48 g, 3.65 mmol). The solution was cooled to – 45 °C and 
treated with trifluoromethane sulfonic acid (0.30 mL, 3.37 mmol) and N-
iodosuccinimide (NIS, 0.70 g, 3.11 mmol). After 30 min, the cooling bath removed and 
kept for 1.5 h before cooling again to – 45 °C to quench the reaction with Et3N (0.80 
mL). The precipitate was removed by filtration and the filtrate was diluted with EtOAc 
(200 mL) and successively washed with 1M aqueous Na2S2O4 (1 ? 60 mL), saturated 
aqueous NaHCO3 (1 ? 60 mL) and brine (1 ? 60 mL).  After removing the solvent the 
residue was purified by flash chromatography over silica gel using 2 ? 5 % MeOH in 
CH2Cl2 to give 0.30 g (73.3%) of 2 as a foam: 1H-NMR (400 MHz, CDCl3) δ 8.17 (d, J 
= 7.0 Hz, 1 H), 7.84 (overlapped br d, 2 H), 7.43 – 7.57 (m, 4 H), 4.88 (s, 1 H), 4.79 (m, 
2 H), 4.70 (d, J = 6.2 Hz, 1 H),  4.32 (d, J = 12.5 Hz, 1 H), 4.00 (m, 1 H), 3.81 (d, J = 
6.2 Hz, 1 H), 3.64 (m, 1 H), 3.29 (d, J = 12.5 Hz, 1 H),  2.65 (m, 2 H), 1.64 (dd, J = 5.4, 
3.5 Hz, 1 H),  1.25 (v br dd, 1 H), 1.03 (m, 28 H),  0.50 (v br ddd, 1 H); 13C NMR (100 
MHz, CDCl3) δ 160.8, 144.3, 132.2, 132.0, 128.0, 126.5, 117.21, 95.8, 93.6, 69.6, 61.8, 
61.5, 61.4, 33.7, 25.5, 21.8, 17.7, 16.4, 16.3, 16.1, 16.0, 15.9, 12.4, 12.1, 12.0, 11.9, 7.7; 
FABMS m/z (relative intensity) 683.3 (MH+, 100), 216.0 (bH2+, 42).  Anal. Calcd. for 
C33H50N4O7Si2•0.50H2O: C, 59.01; H, 7.42; N, 8.10. Found: C, 59.09; H, 7.42; N, 7.85. 
 
Preparation of 3 
A stirred solution of 2 (0.205 g, 0.30 mmol) in MeOH (25 mL) was treated with 
NH4F•0.5H2O (0.412 g, 8.94 mmol) and heated to 55 ºC for 2 h. After cooling to 
ambient temperature, the solvent was removed in vacuo and the residue was purified by 
flash column chromatography over silica gel using 5 ? 10% MeOH in CH2Cl2 to give 
0.119 g (90.10%) of 3 as a foam: 1H-NMR (400 MHz, DMSO-d6) δ 11.30 (s, 1 H),  8.56 
(d, J = 7.4 Hz, 1 H), 8.07 (d, J = 7.4 Hz, 2 H), 7.69 (t, J = 7.4 Hz, 1 H), 7.57 (t, J = 7.8 
Hz, 2 H),  7.40 (br d, J = 6.6 Hz), 5.13 (t, J = 5.0 Hz, 1 H), 4.93 (d, J = 6.6 Hz, 1 H), 
4.80 (s, 1 H), 4.78 (d, J = 7.0 Hz, 1 H),  4.66 (d, J = 8.0 Hz, 1 H), 4.57 (irregular t, 1 H), 
4.13 (dd, J = 11.3, 5.0 Hz, 1 H), 3.79 (t, J = 6.2 Hz, 2 H), 3.74 (d, J = 6.6 Hz, 1 H), 3.20 
(dd, J = 11.3, 4.6 Hz, 1 H), 2.84 (t, J = 6.2 Hz, 2 H), 1.43 (br dd, J ≈ 8, 3 Hz, 1 H), 1.29 
(br t, J = 4.3  Hz, 1 H), 0.70 (v br ddd, 1 H); 13C NMR (100 MHz, CH3OH-d4) δ 162.8, 
146.3, 132.6, 129.0, 128.3, 128.1, 127.7, 118.2, 94.00, 79.5, 70.8, 63.4, 62.5 62.2, 36.7, 
21.6, 17.7, 10.2; FIA-APCl/MS m/z (relative intensity) 441.2 (MH+, 100). HRMS 
(MALDI, positive ion) calcd for C22H24N4O6: 441.1774 (MH+), found: 441.1770. 
 
 
Preparation of 4 
A solution of 3 (0.240 g, 0.54 mmol) in pyridine was thrice evaporated (3 ? 5 mL) and 
finally dissolved in anhydrous pyridine (15 mL).  After cooling over an ice bath, the 
solution was treated with 4,4’-dimethoxytrityl chloride (DMT-Cl, 0.85g; 2.51 mmol) 
and stirred for 30 min. The ice bath was then removed and after 2 h, EtOAc (200 mL) 
was added and the organic layer was washed with water (2 ? 100 mL), dried (MgSO4) 
and concentrated in vacuo. The crude product was purified by flash chromatography 
over silica gel using 0.4% Et3N in EtOAc to give a semisolid product that was triturated 
with hexanes (10 mL), filtered-off and dried in vacuo at 40 ºC for 12 h to give 0.266 g 
(65.8%) of 4 as a foam: 1H-NMR (400 MHz, CH3OH-d4) δ 8.75 (d, J = 7.4 Hz, 1 H), 
7.95 (m, 2 H), 7.20 – 7.63 (m, 13 H), 6.88 (m, 4 H),  4.93 – 5.00 (m, 3 H), 4.05 (m, 1 
H), 3.80 – 3.88 (m, 3 H), 3.78 (2 s, 6 H), 2.72 (irregular t, 2 H), 2.60 (d, J = 10.0 Hz, 1 
H),  1.40 (irregular t, 1 H), 1.28 (m, 1 H), 0.50 (m, 1 H); 13C NMR (100 MHz, CH3OH-
d4) δ 162.8, 158.8, 158.7, 156.8, 146.1, 144.4, 136.2, 135.6, 133.3, 132.6, 129.8, 129.6, 
128.8, 128.0, 127.7, 127.6, 126.6, 118.2, 112.8, 97.7, 93.4, 86.6, 79.0, 71.1, 64.2, 62.9, 
60.1, 54.3, 46.8, 34.7, 22.0, 19.4, 17.7, 10.3. FIA-APCl/MS m/z (relative intensity) 
765.1 (MNa+, 0.3), 303 (DMT+, 100). HRMS (MALDI, positive ion) calcd for 
C43H42N4O8: 743.3081 (MH+), found: 743.3080. Anal. Calcd for C43H42N4O8•0.50 H2O: 
C, 68.69; H, 5.76; N, 7.45. Found: C, 68.89; H, 5.94; N, 7.12. 
 
Preparation of 5 
To a solution of alcohol 4 (229 mg, 0.31 mmol) in CH2Cl2 (3.7 mL) at 0 ºC, DIPEA (77 
µL, 0.44 mmol) and 2-cyanoethyl diisopropylphosphoramidochloridite (198 µL, 0.89 
mmol) were added. After 15 min the reaction was allowed to reach room temperature 
and stirred for 1 h. The reaction was quenched with 5% NaHCO3, extracted with 
CH2Cl2, dried (MgSO4) and concentrated. The residue was purified by silica column 
chromatography (hexanes/EtOAc 30:70 + 2% Et3N) to give 262 mg (90%) of 5 as a 
mixture of diastereoisomers; 1H NMR (400 MHz, CDCl3) δ 8.70 (d, J = 7.6 Hz, 1 H), 
8.61 (bs, 1H), 7.90-7.89 (m, 2 H), 7.63-7.21 (m, 13 H), 6.91-6.89 (m, 4 H), 5.12-4.76 
(m, 4 H), 4.24-4.09 (m, 3 H), 3.99 (m, 1 H), 3.86 (m, 6 H), 3.73-3.52 (m, 4 H), 2.83-
2.49 (m, 5 H), 1.55-1.20 (m, 14 H), 0.55 (m, 1 H). 13C NMR (100 MHz, CDCl3) δ 
161.7, 161.6, 158.6, 158.6, 158.5, 144.2, 144.1, 135.9, 135.8, 135.5, 133.0, 132.9, 
130.1, 130.0, 129.9, 129.9, 128.9, 128.3, 128.1, 128.0, 127.9, 127.5, 118.5, 118.2, 
117.6, 117.5, 113.3, 113.2, 95.0 (d, J = 4.6 Hz), 94.7, 86.7, 86.6, 79.1-79.2 (m), 74.0 (d, 
J = 14.0 Hz), 72.7 (d, J = 10.2 Hz), 64.0, 63.9, 63.8, 63.7, 63.1, 62.9 (m), 62.5, 58.1, 
58.0, 55.2, 55.1, 45.3, 45.2, 43.1 (dd, J = 2.9 Hz, J = 12.6 Hz), 35.0 (m), 34.8 (m), 25.7, 
25.6, 24.8, 24.7, 24.6, 22.9, 22.6, 20.4, 20.3, 20.1, 20.0, 18.7, 18.6, 11.8, 11.7. 31P NMR 
(110 MHz, CDCl3) δ 150.8, 149.0. HR-ES-MS [M + H]+ Calcd. for C52H60N6O9P: 
943.4159, found: 943.4149. 
 
 
 
 
 
 
 
Solid-phase oligonucleotide synthesis 
 
RNA oligonucleotides were synthesized on the 0.2 µmol scale on an Applied 
Biosystems 394 synthesizer using 2'-O-TBDMS protected phosphoramidites (ABz, Gdmf, 
CAc and U). Commercially available succinyl polystyrene functionalized with 5’-O-
DMT-2’-deoxythymidine was used as the solid support. The following solutions were 
used: 0.4 M 1H-tetrazole in ACN (activation); 3% trichloroacetic acid in DCM 
(detritylation), acetic anhydride/pyridine/ tetrahydrofuran (1:1:8) (capping A), 10% N-
methylimidazole in tetrahydrofuran (capping B), 0.01 M iodine in 
tetrahydrofuran/pyridine/water (7:2:1) (P (III) to P (V) oxidation; for the unmodified 
sense and guide (6, wt) oligonucleotides), 10% tert-butyl hydroperoxide in 
acetonitrile/water (96:4) (P (III) to P (V) oxidation; for the modified guide strands 7 and 
8). The coupling time was 15 min. All oligonucleotides were synthesized in DMT-ON 
mode. 
 
 
Deprotection and purification of unmodified sense and guide (6, wt) 
oligonucleotides  
 
After the solid-phase synthesis, the solid support was transferred to a screw-cap glass 
vial and incubated at 55 ºC for 1 h with 1.5 mL of NH3 solution (33%) and 0.5 mL of 
ethanol. The vial was then cooled on ice and the supernatant was transferred into a 2 mL 
eppendorf tube. The solid support and vial were rinsed with 50% ethanol (2 x 0.25 mL). 
The combined solutions were evaporated to dryness using an evaporating centrifuge. 
The residue that was obtained was dissolved in a total volume of 85 µL of 1M TBAF in 
THF and rocked at room temperature for 12 h. Then, 85 µL of 1M triethylammonium 
acetate (TEAA) and 330 µL of water were added to the solution. The oligonucleotide 
was desalted on a NAP-5 column using water as the eluent and evaporated to dryness. 
The oligonucleotide was purified by HPLC (DMT-ON). Column: Nucleosil 120-10 C18 
(250x4 mm); 20 min linear gradient from 15%  to 80% B and 5 min 80% B, flow rate 3 
mL/min; solution A was 5% ACN in 0.1 M aqueous TEAA and B 70% ACN in 0.1 M 
aqueous TEAA.  
The pure fractions were combined and evaporated to dryness. The residue that was 
obtained was treated with 1 mL of 80% AcOH solution and incubated at room 
temperature for 30 min. The deprotected oligonucleotide was desalted on a NAP-10 
column using water as the eluent. All oligonucleotides were quantified by absorption at 
260 nm and confirmed by MALDI mass spectrometry.  
 
 
Deprotection and purification of modified oligonucleotides 7 and 8 
 
After the solid-phase synthesis, the solid support was transferred to a screw-cap glass 
vial and incubated at 35 ºC for 24 h with 1.5 mL of NH3 solution (33%) and 0.5 mL of 
ethanol. The vial was then cooled on ice and the supernatant was transferred into a 2 mL 
eppendorf tube. The solid support and vial were rinsed with 50% ethanol (2 x 0.25 mL). 
The combined solutions were evaporated to dryness using an evaporating centrifuge. 
The residue that was obtained was dissolved in a mixture formed by 10 µL of n-
propylamine, 1 µL bis(2-mercaptoethyl) ether and of 100 µL of 1M TBAF in THF and 
rocked at room temperature for 24 h. Then, 100 µL of 1M triethylammonium acetate 
(TEAA) and 289 µL of water were added to the solution. The oligonucleotide was 
desalted on a NAP-5 column using water as the eluent and evaporated to dryness. The 
oligonucleotide was purified by HPLC (DMT-ON). Column: Nucleosil 120-10 C18 
(250x4 mm); 20 min linear gradient from 15%  to 80% B and 5 min 80% B, flow rate 3 
mL/min; solution A was 5% ACN in 0.1 M aqueous TEAA and B 70% ACN in 0.1 M 
aqueous TEAA.  
The pure fractions were combined and evaporated to dryness. The residue that was 
obtained was treated with 1 mL of 80% AcOH solution and incubated at room 
temperature for 30 min. The deprotected oligonucleotide was desalted on a NAP-10 
column using water as the eluent. All oligonucleotides were quantified by absorption at 
260 nm and confirmed by MALDI mass spectrometry.  
 
 
General procedure for enzymatic digestion of oligonucleotides 
 
Each RNA oligomer (0.4 OD units at 260 nm) was incubated with nuclease P1 (0.5 
units) at 37 ºC for 24 h. Then alkaline phosphatase (1 unit) and buffer (50 mM Tris-
HCl, pH 9.3, containing 1 mM MgCl2, 0.1 mM ZnCl2 and 1 mM spermidine, final 
concentrations) were added to give a total volume of 230 μL and the mixture was 
incubated at 37 ºC for a further 24 h. The reaction mixture was analyzed by HPLC. 
 
 
UV-monitored thermal denaturation studies 
 
Absorbance versus temperature curves of duplexes were measured at 1 µM strand 
concentration in 15 mM HEPES-KOH (pH 7.4), 1 mM MgCl2 and 50 mM potassium 
acetate buffer. Experiments were performed in Teflon-stoppered 1 cm path lenght 
quartz cells on a JACSO V-650 spectrophotometer equipped with thermoprogrammer. 
The samples were heated to 90 ºC, allowed to slowly cool to 25 ºC, and then warmed 
during the denaturation experiments at a rate of 1 ºC/min to 85 ºC, monitoring 
absorbance 260 nm. The data were analyzed by the denaturation curve processing 
program, MeltWin v. 3.0. Melting temperatures (Tm) were determined by computerfit of 
the first derivative of absorbance with respect to 1/T. 
 
 
RNAi methods 
 
SH-SY5Y were grown at 37 ºC in Dulbecco’s modified Eagle medium (DMEM; 
GIBCO) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 
100 µg/mL streptomycin. Cells were regularly passaged to mantain exponential growth. 
Twenty-four hours before transfection at 50–80% confluency, mammalian cells were 
trypsinized and diluted 1:5 with fresh medium without antibiotics (1–3 x 105 cells/mL) 
and transferred to 24-well plates (500 µL per well). Two luciferase plasmids, Renilla 
luciferase (pRL-TK) and Firefly luciferase (pGL3) from Promega, were used as a 
reporter and control, respectively. Cotransfection of plasmids and siRNAs was carried 
out with Lipofectamine 2000 (Life Technologies) as described by the manufacturer for 
adherent cell lines. Per well, 1.0 µg pGL3-Control, 0.1 µg pRL-TK and 0.03–26 nM 
siRNA duplex formulated into liposomes, were applied; the final volume was 600 µL 
per well. The cells were harvested 22 h after transfection, and lysed using passive lysis 
buffer, 100 µL per well, according to the instructions of the Dual-Luciferase Reporter 
Assay System (Promega). The luciferase activities of the samples were measured using 
a MicroLumaPlus LB 96V (Berthold Technologies) with a delay time of 2 s and an 
integrate time of 10 s. The following volumes were used: 20 µL of sample and 30 µL of 
each reagent (Luciferase Assay Reagent II and Stop and Glo Reagent). The inhibitory 
effects generated by siRNAs were expressed as normalized ratios between the activities 
of the reporter (Renilla) luciferase gene and the control (Firefly) luciferase gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. 1H-NMR spectrum of compound 2s 
 
 
 
 
Figure S2. 13C-NMR spectrum of compound 2s 
 
 
 
Figure S3. 1H-NMR spectrum of compound 3s 
 
 
 
 
 
Figure S4. 13C-NMR spectrum of compound 3s 
 
 
Figure S5. 1H-NMR spectrum of compound 4s 
 
 
 
Figure S6. 13C-NMR spectrum of compound 4s 
 
 
 
 
Figure S7. 1H-NMR spectrum of compound 5s 
 
 
Figure S8. 13C-NMR spectrum of compound 5s 
 
 
 
 
 
 
 
Figure S9. 1H-NMR spectrum of compound 6s 
 
 
 
Figure S10. 13C-NMR spectrum of compound 6s 
 
 
 
 
Figure S11. 1H-NMR spectrum of compound 7s 
 
 
Figure S12. 13C-NMR spectrum of compound 7s 
 
 
 
Figure S13. 1H-NMR spectrum of compound 8s 
 
 
 
Figure S14. 13C-NMR spectrum of compound 8s 
 
 
 
 
 
Figure S15. 1H-NMR spectrum of compound 1 
 
 
Figure S16. 13C-NMR spectrum of compound 1 
 
 
 
 
Figure S17. 1H-NMR spectrum of compound 2 
 
 
Figure S18. 13C-NMR spectrum of compound 2 
 
 
 
 
 
Figure S19. 1H-NMR spectrum of compound 3 
 
 
 
 
Figure S20. 13C-NMR spectrum of compound 3 
 
 
Figure S21. 1H-NMR spectrum of compound 4 
 
 
 
Figure S22. 13C-NMR spectrum of compound 4 
 
 
 
Figure S23. 1H-NMR spectrum of compound 5 
 
Figure S24. 13C-NMR spectrum of compound 5 
 
 
Figure S25. 31P-NMR spectrum of compound 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S1. MALDI-TOF mass spectra of synthesized oligonucleotides 
 
Oligonucleotide Sequence MW calcd. MW 
found 
sense 3'-TTAAAAAGAGGAAGAAGUCUA-5' 6790.0 6787.6 
guide, 6 (wt) 5'-UUUUUCUCCUUCUUCAGAUTT-3' 6423.0 6426.4 
guide, 7 5'-UUUUUCUCNCUUCUUCAGAUTT-3' 6431.0 6441.8 
guide, 8 5'-UUUUUCUCNCUUCUUCNAGAUTT-3' 6464.6 6470.8 
scr-ss  3'-TTAGGAAAGAAAGAAAGCUAU-5' 6790 6796.5 
scr-guide 5'-UCCUUUCUUUCUUUCGAUATT-3' 6421.3 6425.4 
    
 
 
 
Figure S26. MALDI-TOF mass spectra of synthesized oligonucleotides 
 
Guide strand 7 
 
 
 
 
 
 
 
Guide strand 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S27. Plot of gene-specific RNAi activity for siRNAs formed by  
unmodified guide strand 6 and modified guide strands 7 and 8 expressed in  
SH-SY5Y cells 
 
 
 
 
